Vaccines

New research out of the University of Pennsylvania on a DNA-based Zika virus vaccine is showing promising results.

Scientists from the National Institute of Allergy and Infectious Diseases have discovered a broadly neutralizing antibody that is able to neutralize 98% of HIV strains.

A recent analysis by the Centers for Disease Control and Prevention found that strides have been made in the fight against measles; however, the work still falls short of goals set by the World Health Assembly (WHA).

A new potential case of the Ebola virus has been reported in Canada.

Satellite images of nighttime lights can improve vaccination coverage in shifting populations.

A new study has found no correlation between receiving the Tdap vaccine during pregnancy and birth defects.

Human trials are currently underway for a potential candidate vaccine for the Zika virus and a novel treatment approach has shown promise in mice.

Despite the Centers for Disease Control and Prevention's recommendation that the human papillomavirus (HPV) vaccine be routinely given to adolescents and young adults, administration rates for the vaccine are still low.

Researchers in the United States and South Korea recently studied the use of an experimental nanoparticle treatment that acts as a decoy to stop and kill the influenza virus.

Public-health experts recommend that the seasonal influenza vaccine be available in more non-medical settings in hopes that with increased accessibility, more people will choose to get vaccinated.

Researchers have not been able to develop a vaccine for hepatitis C, which causes 700,000 deaths around the world annually, and now, a new study shows why developing a vaccine for the virus has been so difficult.

Researchers estimate that there are more cases of sclerosing panencephalitis (SSPE), a fatal measles complication, than previous thought.

“The number of people who experience the devastating effects of preventable infectious diseases like measles, diphtheria, and whooping cough is at an all-time low," according to the Centers for Disease Control and Prevention (CDC).

The probability of a measles epidemic occurring in Texas increases as the number of children exempt from receiving the measles vaccine continues to grow.

During ID Week, Robert Read, MD, from University Hospital Southampton in Southampton, UK, discussed how a better understanding of meningococcal disease has led to more effective treatment strategies.

Rebekah Stewart Schicker, MSN, MPH, APRN, Epidemic Intelligence Service (EIS) Officer at the Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Influenza Division, discusses which outpatient populations are at highest risk of influenza-associated complications and the recommended treatments for these individuals.

The nation’s top public health officials believes the disease is destined to spread across the United States in the coming months.

Vaccines are generally quite safe, but a recent study of BCG, DTP, and MCV raises concerns that warrant further exploration.

The United Nations Children’s Fund (UNICEF) has partnered with six vaccine makers and the Global Alliance for Vaccines and Immunization (GAVI) to offer 450 million doses of an inexpensive pentavalent vaccine for children.

Changes in strain prevalence indicate that the existing 9-valent HPV vaccines may offer some protection against an additional high-risk strain that is not included in the vaccine (strain 31), potentially due to antigenic similarities with other strains.

Stephen Redd, MD (RADM, USPHS), Director of the Office of Public Health Preparedness and Response (OPHPR) at the Centers for Disease Control and Prevention (CDC), discusses the 2016-2017 flu vaccine.

A mutated version of Yersinia pestis may hold the key to vaccines for the plague.

Researchers at Sanofi Pasteur, have developed a “transmission model” for Dengue and assessed the population impact of vaccination in the 10 countries participating in the Phase III efficacy studies for CYD-TDV/Dengvaxia.

The US Food and Drug Administration has approved its quadrivalent formulation of the Flublok influenza vaccine.